Clinical Lymphoma & Myeloma is committed to bringing cutting-edge, disease-specific data to the practicing hematologist and oncologist. Each issue of Clinical Lymphoma & Myeloma features peer-reviewed original contributions, invited comprehensive reviews, and current trials reports, as well as "Meeting Highlights" and "Mini-Review" reports taken from major oncology meetings each year. Also included are brief editorials of current news and the latest topics concerning Lymphoma and Myeloma for the clinician.



Editors-in-Chief
James O. Armitage
University of Nebraska Medical Center
Omaha, Nebraska

Bruce D. Cheson
Georgetown University Hospital
Lombardi Cancer Center
Washington, D.C.

Sundar Jagannath
St. Vincent’s Comprehensive Cancer Center
New York, New York

Vinay K. Jain
Baylor Charles A. Sammons Cancer Center
Dallas, Texas


Associate Editor
Marvin J. Stone
Baylor-Charles A. Sammons Cancer Center
Dallas, Texas

Section Editor
Brian G. M. Durie
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California


Director of Publications
Jasper Simons
Dallas, Texas


Indexed
Index Medicus/PubMed
ISI-Current contents/Clinical
Medicine and Research Alert
Science Citation Index
Expanded (Web of Science)
EMBASE Excerpta Medica
CINAHL (Cumulative Index to Nursing and Allied Health
Literature®)


Editorial Board

Lymphoma
Agustin Avilés

Mexico City, Mexico

Hamdy F. Azim
Cairo, Egypt

James R. Berenson
Los Angeles, California

P. Leif Bergsagel
New York, New York

Philip J. Bierman
Omaha, Nebraska

J. Magnus Björkholm
Stockholm, Sweden

Franco Cavalli
Bellinzona, Switzerland

Bertrand Coiffier
Pierre-Bénite, France

Madeleine Duvic
Houston, Texas

James M. Foran
Omaha, Nebraska

Francine M. Foss
Boston, Massachusetts

Christian Gisselbrecht
Paris, France

Andrew Grigg
Melbourne, Australia

Michael L. Grossbard
New York, New York

Anton Hagenbeek
Utrecht, The Netherlands

Wolfgang Hiddemann
Munich, Germany

Richard T. Hoppe
Stanford, California

Sandra J. Horning
Palo Alto, California

Tanin Intragumtornchai
Bangkok, Thailand

Peter Jacobs
Cape Town, South Africa

Elaine S. Jaffe
Bethesda, Maryland

Mark S. Kaminski
Ann Arbor, Michigan

Lawrence D. Kaplan
San Francisco, California

Richard J. Klasa
Vancouver, Canada

Boris Labar
Zagreb, Croatia

David Leibowitz
Palo Alto, California

Charles F. LeMaistre
San Antonio, Texas

Raymond Liang
Pokfulam, Hong Kong

Thomas A. Lister
London, United Kingdom

Dan L. Longo
Baltimore, Maryland
David G. Maloney
Seattle, Washington

Peter McLaughlin
Houston, Texas

Emilio Montserrat
Barcelona, Spain

Bharat N. Nathwani
Los Angeles, California

Andrei A. Novik
St. Petersburg, Russia

Santiago Pavlovsky
Buenos Aires, Argentina

Lode J. Swinnen
Maywood, Illinois

Kensei Tobinai
Tokyo, Japan

George Weiner
Iowa City, Iowa

Dennis D.Weisenburger
Omaha, Nebraska

Lynn D. Wilson
New Haven, Connecticut

Wyndham H. Wilson
Bethesda, Maryland

Emanuele Zucca
Bellinzona, Switzerland

Myeloma
Melissa Alsina
Tampa, Florida

Kenneth C. Anderson
Boston, Massachusetts

Michel Attal
Toulouse, France

Bart Barlogie
Little Rock, Arkansas

Joan Bladé
Barcelona, Spain

Mario Boccadoro

Turin, Italy

Asher A. Chanan-Khan
Buffalo, New York

Raymond L. Comenzo
New York, New York

Morie A. Gertz
Rochester, Minnesota

Jean-Luc Harousseau
Nantes, France

Douglas E. Joshua
Camperdown, Australia

Robert A. Kyle
Rochester, Minnesota

John P. Leonard
New York, New York

Nikhil C. Munshi
Boston, Massachusetts

Pieter Sonneveld
Rotterdam, The Netherlands

Steven P. Treon
Boston, Massachusetts

Scope
Clinical Lymphoma & Myeloma is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma and myeloma. Clinical Lymphoma & Myeloma is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma and myeloma. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Editorial Policies
Submitted manuscripts must be original articles of high quality. Please note that only original manuscripts with data not published earlier or under simultaneous consideration by other journals are invited for inclusion. Journal policy requires that authors reveal in a letter to the Editors-in-Chief any relationships that may be construed as conflicts of interest with regard to the manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

The Publisher endorses the principles embodied in the Declaration of Helsinki and expects that all investigations involving human subjects were performed in accordance with these principles. The investigator’s institutional review board must have approved all human studies.

The manuscript cover letter must state that all persons listed as authors have contributed to the study and in preparing the manuscript. Authors will be asked to transfer copyright of articles accepted for publication to CIG Media Group, LP.

Manuscript Preparation

Style
Articles should be written clearly and concisely. Submit an electronic copy at www.cigjournals.com, or submit 1 original and 3 hard copies by mail. The manuscript must be typed and double-spaced. Fonts should be 10 points or larger; margins should be 1 inch all around. Number pages consecutively beginning with the title page. All copies must contain a complete set of tables, figures, and legends.

Title page
Provide an appropriate title describing the subject matter of the manuscript. List the first names, middle initials, and last names of authors with their institutional affiliation. Provide the name, complete mailing address, phone/fax number, and e-mail address of the corresponding author. Provide an abbreviated title of ≤ 100 characters. Provide 4-6 simple key words. These should be words that do not appear in the title. Do not use abbreviations or commercial names in the title or the abbreviated title.

Abstract
Provide an unstructured abstract of no more than 250 words on a separate page. Original Contributions should include a structured abstract with the following sections: Background, Materials (or Patients) and Methods, Results, Conclusion.

Text
Introduction. In 1 to 2 pages, indicate why the topic is important and state the specific objective(s) of the study.


Patients and Methods or Material and Methods. In 1 to 3 pages, describe the methods, equipment, and techniques used as well as details of the protocols. Add a paragraph to describe the statistical methods used.

Results. In 2 to 4 pages, succinctly describe the results obtained. Describe how observations across studies were tabulated and integrated.

Discussion. In 2 to 4 pages, focus the discussion on the findings of the current work. If applicable, include a comparison of the results to those found in similar studies.

Conclusion. In 1 to 2 pages, summarize the findings from the current study, including clinical implications and the need for additional research.

Figures, Tables, and Legends. Lettering and identifying marks (arrows) must be clear, sharp, and large enough to see when published. Figures should have a resolution of at least 300 dpi. Identify the critical area(s) of x-rays, MRIs, PETs, SPECTs, CTs, and photomicrographs. Type all legends on a single, separate page, not on the figure itself, and define any abbreviations found in the figure. For tables, explanatory footnotes may be used if needed, all abbreviations used should be defined, and sufficient information must be included to make the table self-explanatory. Do not use a table for data that can be described adequately in 2-3 sentences in the text. If a previously published figure or table is to be used, a letter of permission from the copyright holder must be provided by the corresponding author upon acceptance of the manuscript.

References
Authors are responsible for the accuracy of all references. The format must adhere to the specifications of the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” promulgated by the International Committee of Medical Journal Editors (N Engl J Med 1997; 336:309-315). References are numbered consecutively in the order they appear in the text. References appearing for the first time in a table or figure should be cited in the text where the table or figure is mentioned. Citations are in superscript. Each reference must be cited. Journal names should be abbreviated according to the style of Index Medicus, National Library of Medicine.

Please note that no periods are used after the authors’ initials or after journal abbreviations given in the reference list; “et al” is used when there are more than 3 authors. There is a period at the end of each reference. Abstracts must include volume, page, and abstract numbers.

Manuscript Review
Manuscripts are screened for completeness. Receipt of the manuscript is acknowledged. All manuscripts are subjected to peer review, typically 2 in number. Usually one of the reviewers is a member of the Editorial Board and the other is an outside expert chosen for his/her knowledge and scope of the subject matter of the manuscript.

Authors may suggest the name of a specific reviewer whom they believe to be particularly qualified to review the manuscript. If you do not wish to have your manuscript reviewed by a particular reviewer, you may state so. All such requests are regarded as confidential and will be considered by the Editor-in-Chief when assigning reviewers.

Accepted Manuscripts
Upon acceptance for publication, the manuscript is copyedited. The galley proofs of the manuscript are sent to the corresponding author for final review. The authors must check proofs carefully and make only necessary changes. The author should return the galley proofs to the publisher via fax or overnight mail within 24-48 hours as requested.

Types of Articles
Comprehensive Review
Review articles (2000-5000 words) collate, describe, and evaluate prior publications of important clinical subjects related to lymphoma and/or myeloma, accompanied by critical analysis leading to rational conclusions.

Original Contribution

Original contribution articles (2000-4000 words) present results of original clinical research that is relevant to lymphoma and/or myeloma. Include a structured abstract.

Case Reports
Case reports (500-1500 words) of educational value may describe a single case or a small series of cases. Case reports should draw attention to important clinical situations, unusual clinical phenomena, new treatment protocols, or new complications.

Current Trials
Current trials (500-1500 words) of educational value describe the rationale, criteria, treatment plan, and anticipated results. They may describe a small series of cases.

Translational Medicine

Translational medicine articles (3000-5000 words) deal with basic research with clinical application, describing development of basic research and presenting basic research data as well as data obtained from human samples or patients. A discussion of how this translational approach impacts the treatment of patients with lymphoma/myeloma is essential.

Imaging in Lymphoma

Imaging articles deal with novel diagnostic imaging techniques, eg, MRI, CT, PET, SPECT. Modalities for diagnostic purposes, on outcome according to the pathologic grade or to monitor distant lesions, are of interest to the readership. Articles submitted may describe individual cases (1500-2000 words) or series of cases (2000-3000 words).

Clinical Concepts and Commentary
Clinical concepts articles and commentaries (1000-2500 words) are by invitation only and focus on clinical topics that are novel or controversial and require rapid dissemination.

Letter to the Editor
These articles should be brief (250-500 words). A few references, a small table, or a pertinent illustration may be used.

Brief Communication
Brief communication articles (500-1500 words) should include a maximum of 2 tables and 2 figures.

Other Items

Clinical Lymphoma & Myeloma publishes highlights/reports of scientific meetings and book reviews. Please contact the editorial office for further information.

Submission of Manuscripts

Manuscripts should be submitted electronically at www.cigjournals.com. Click on the specific journal, and follow the prompts. Manuscripts can be Microsoft Word files containing the text, tables, and figures. Full instructions can be found on the journal Web site.

Editors-in-Chief, Clinical Lymphoma & Myeloma
3500 Maple Avenue, Suite 750, Dallas, TX 75219-3931 USA
Phone: 214-367-3350; Fax: 214-367-3301


Permissions
Lengthy direct quotations, tables, or figures from previously published sources must be accompanied by written permission from the copyright holder. Complete information of the source of the material also must be provided. No part of the materials published in Clinical Lymphoma & Myeloma may be reproduced without written permission. If you require assistance with the permission process, please contact the editorial office at 214-367-3350.



Click on the links below to download a PDF format of the Advertising Rate and Mechanical Requirements Card


Advertising Rate and Mechanical Requirements Card

Journal Information


If you do not have Adobe Acrobat, you may download it by clicking the banner below





Click on the links below to download a PDF format of the Subscription Card

Subscription Card

If you do not have Adobe Acrobat, you may download it by clicking the banner below


For Reviewers

Instructions relevant to the peer-review process can be found on the "Reviewer Instructions" page of the online submission site.



home | publications | news | contact